Hoth Therapeutics, a clinical-stage biopharmaceutical company, has allocated up to $1 million to Bitcoin, leveraging the cryptocurrency's potential as a store of value and hedge against inflation. This decision, approved by the company's board of directors, reflects a broader trend of business adoption for Bitcoin in the U.S., fueled by renewed interest following Donald Trump’s reelection as president. Hoth's CEO Robb Knie emphasized the role of investor attention and market activity, including the approval of Bitcoin exchange-traded funds (ETFs), in this strategic treasury move. U.S. Senator Cynthia Lummis has previously suggested that the U.S. Treasury convert part of its gold reserves into Bitcoin, advocating for Washington to consider cryptocurrency as a viable asset. Other figures in the financial sector, like MicroStrategy's Michael Saylor, are also supporting Bitcoin investments, signaling a growing recognition of its inflation-resistant qualities among institutions.

Source 🔗